Primary tumour location as a prognostic factor for survival in neuroendocrine tumor in HUSM : 10 years review by Shah, Muhammad Ezzra Shah Rahman
 ii 
PRIMARY TUMOUR LOCATION AS A PROGNOSTIC 
FACTOR FOR SURVIVAL IN NEUROENDOCRINE 
TUMOUR IN HUSM : 10 YEARS REVIEW 
 
 
 
 
 
BY 
 
 
 
 
MUHAMMAD EZZRA SHAH BIN RAHMAN SHAH 
 
 
Dissertation Submitted In 
 Partial Fulfillment of The Requirement For  
The Degree of Master of Medicine 
 (Surgery) 
 
 
 
 
 
NOVEMBER 2017 
 
 
 
 
 iii 
ACKNOWLEDGEMENTS 
 
I would like to thank Almighty Allah for the opportunity to be part of this thesis, for the time 
and energy given to me to complete the project. Alhamdulillah! 
I would like to express my gratitude to my supervisor, Dr Maya Mazuwin Yahya, who 
supported me all the way from the beginning. She helped me with the topic and supervised 
me all the way. Thanks to her I managed to complete the thesis on time. She gave me 
scientific guidance and advice, assisted me in solving problems and encouraged my research 
progress. 
Thanks to my head of department, Prof Zaidi Zakaria, who always give his views and 
encouraged us to complete the thesis. Without him, for sure we cannot manage this. I also 
would like to acknowledge the support of my surgical department and university who gave 
me generous access to the facilities provided. Thanks to my friends advising during the 
project. 
Thousand thanks to my dearest wife for encouraging me day and night completing the thesis. 
She was my backbone throughout my 4 years of master programme. I love her very much! 
Finally, I sincerely thank my parents who were there to support me during my master 
programme and obviously they indirectly involved in helping me complete my thesis. Not to 
miss also my siblings. 
Thank you! 
 
 iv 
TABLE OF CONTENTS 
               PAGE 
ACKNOWLEDGEMENTS       ii 
TABLE OF CONTENTS       iii 
LIST OF TABLES        iv 
LIST OF FIGURES        v 
LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS  vi - vii 
ABSTRAK          viii - ix 
ABSTRACT         x - xi 
 
 
CHAPTER 1.0 - INTRODUCTION 
 
1.1  INTRODUCTION       1 - 2 
1.2  LITERATURE REVIEW      3 - 6 
1.3  RATIONAL OF STUDY      7 
 
CHAPTER 2.0 - STUDY PROTOCOL 
 
 2.1 DOCUMENT SUBMITTED FOR ETHICAL APPROVAL 8 - 24 
 2.2 ETHICAL APPROVAL LETTER     25 - 27 
 
CHAPTER 3.0 – BODY 
 
 3.1 TITLE PAGE        28 
 3.2 ABSTRACT        29 - 30 
 3.3 INTRODUCTION       31 - 32 
 3.4 METHODOLOGY       33 - 34 
 3.5 RESULTS        35 - 41 
 3.6 DISCUSSION        42 - 60 
 3.7 REFERENCES       60 - 65 
 
CHAPTER 4.0 – APPENDICES      66 - 67 
   
 
 v 
LIST OF TABLES 
 
 
Table 1: Demographic data regarding patient’s characteristic   Page 35 
Table 2: The association between primary tumour location and metastasis  Page 39 
Table 3: The five years disease free survival in NET according   Page 40 
               to primary tumour location 
Table 4: Primary tumour location as prognostic factor for survival in NET  Page 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
LIST OF FIGURES 
 
 
Figure 1: Distribution of tumour location based on stages    Page 38 
Figure 2: Kaplan Meier curve for survival of NET based on    Page 40 
               primary tumour location  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMNS 
 
Neuroendocrine tumour       NET 
Gastroenteropancreatic neuroendocrine tumour     GPNET 
Histopathological examinations       HPE 
Computed tomography       CT 
Gastrointestinal tract        GIT 
5-hydroxyindoleacetic acid        5-HIAA 
Magnetic resonance imaging        MRI 
Endoscopic ultrasound        EUS  
Somatostatin receptor scintigraphy       SRS 
Positron emission tomography       PET 
Fluorodeoxyglucose         FDG 
Pancreatic polypeptide        PP 
Chromogranin A        CgA 
Peptide receptor radionuclide therapy      PRRT 
Radiofrequency ablation        RFA  
 viii 
Trans-arterial embolization        TAE 
Trans-arterial chemo-embolization       TACE 
Selective internal radiation therapy       SIRT 
World Health Organization       WHO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
ABSTRAK 
 
 
Latar belakang 
Kes tumor neuroendocrine semakin meningkat dan jumlahnya berganda jika dibandingkan 
dengan dekad yang lalu. Tumor neuroendocrine biasanya hadir dengan pelbagai cara dan ini 
menyebabkan ia amat sukar untuk di diagnos. Pada masa ini, dengan kecanggihan teknologi 
yang baharu, tumor neuroendocrine lebih mudah untuk dikesan dan dirawat. Tumor 
neuroendocrine merangkumi spektrum penyakit yang boleh dirawat secara pembedahan atau 
bukan pembedahan. Ia selalu dikaitkan dengan pelbagai gejala dan tanda-tanda. Antara yang 
paling penting adalah sindrom ‘carcinoid’. Tumor neuroendocrine juga boleh dikesan secara 
kebetulan semasa pemeriksaan rutin. Kebanyakan pesakit tumor neuroendocrine hadir pada 
tahap keempat dengan metastasis. Tumor neuroendocrine boleh dikesan dengan 
menggunakan serum ‘chromogranin A’. Lokasi tumor neuroendocrine boleh dikesan 
menggunakan pengimejan seperti imbas CT, imbas MRI dan imbas PET. Adalah sangat 
mustahak untuk mengetahui lokasi tumor kerana prognosis dikaitkan dengannya. 
 
 
Metodology 
Rekod-rekod pesakit tumor neuroendocrine di Hospital Universiti Sains Malaysia dari 
Januari 2005 hingga Disember 2015 akan dikaji semula. Sejumlah 48 pesakit-pesakit yang 
memenuhi ciri-ciri kemasukan dan ciri-ciri pengecualian akan diambil untuk kajian ini. 
Senarai pesakit diambil dari pejabat rekod. Rekod pesakit akan dikaji dan data-data akan 
dimasukkan ke dalam borang koleksi. Data-data seperti umur, jantina, gejala-gejala, lokasi 
tumor, maklumat pembedahan, maklumat histopatologi, pengimejan, biomarker, tahap 
penyakit, dan hasil rawatan akan dianalisis. 
 ix 
Keputusan  
Analisis kaitan antara data lokasi tumor dan prognosis akan dianalisis. Kaitan jangka masa 
hidup lima tahun bebas dari penyakit bagi pesakit akan dianggarkan menggunakan analisis 
Kaplan-Meier. Jangka masa hidup adalah tinggi bagi tumor di lokasi payudara (85 bulan) dan 
rendah di lokasi paru-paru dan pleura (9.7 bulan). Perbandingan adalah sangat jelas dan 
penting bagi semua lokasi tumor kecuali lokasi paru-paru, pleura dan pangkal rahim. Masa 
hidup median adalah tinggi pada lokasi tumor ‘other’ (30 bulan) dan rendah pada lokasi 
‘unknown’ (7 bulan). 
 
 
 
Kesimpulan  
Kajian kami menunjukkan bahawa lokasi tumor adalah satu faktor prognosis yang penting 
bagi menentukan jangka masa hidup bagi pesakit-pesakit tumor neuroendocrine. Lokasi 
tumor di payudara, appendik dan usus besar mempunyai jangka masa hidup yang tinggi. 
Namun begitu, tumor di lokasi ‘unknown’ dan lokasi paru-paru dan pleura mempunyai 
jangka masa hidup yang rendah. 
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ABSTRACT 
 
Background  
Neuroendocrine tumour is on the rise. The incidents doubled compared to last decade. It 
presents with a variety of manifestations and sometimes become a challenge to diagnose. 
Currently, with the modern technology, neuroendocrine tumour (NET) can be detected and 
managed accordingly. Neuroendocrine tumour is a spectrum of disease which can be 
managed surgically or non-surgically. It is associated with wide range of symptoms and 
signs. The most important is the carcinoid syndrome. Sometimes, NETs are found 
incidentally during routine check-up and imaging. Most of the time, patients presented with 
evidence of metastasis (stage 4 disease).  NETs can be detected using serum chromogranin A. 
Primary tumour localization can be found using imaging such as CT, MRI or PET scan. It is 
important to know the primary tumour localization as prognosis is associated with it.  
 
Methodology 
All patients who are diagnosed with neuroendocrine tumour in Hospital Universiti Sains 
Malaysia from January 2005 to December 2015 are retrospectively reviewed. A total of 48 
patients who met the inclusions and exclusion criteria were enrolled for this study. List of the 
patients is obtained from record office. The medical records of patients that recruited in the 
study will be reviewed and the data will be entered into the data collection form. The data 
(age, gender, patient’s symptoms, primary tumour location, surgical information, 
histopathological examination findings, imaging, biomarkers, stage of disease, and patient’s 
outcome) will be analysed. Descriptive analysis will be done using mean and standard 
deviation for numerical variables and frequency and proportion for categorical variables.  
 
 xi 
Result 
Association of primary tumour location and survival was analysed. Five-years disease free 
survival in NET according to primary tumor location estimated by Kaplan-Meier analysis. 
The survival rate was high in tumor in breast ( 85 months)  and lower in lung and pleura (9.7 
months). The comparisons were significant in all tumor location except in lung, pleura and 
cervix. The median survival time were high in other tumor location (30.0 months) and lower 
in unknown location ( 7.0 months). 
 
 
Conclusion 
Our study demonstrated that primary tumour location is a prognostic factor for survival in 
neuroendocrine tumour. Primary tumour location in breast, appendix and colorectal have 
better survival while NET with unknown primary tumour location and in lung or pleura have 
poor survival. 
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CHAPTER 1.0 – INTRODUCTION 
 
 
1.1 – INTRODUCTION 
 
 
Neuroendocrine tumour (NET) is a mass that begins in the parts of the body that produce 
and release hormones. Neuroendocrine tumours are rare tumours. However, there has been a 
steady increase in incidence and prevalence of neuroendocrine tumours over the last decade. 
Studies from United States and Europe have shown the that the disease is on the rise. This is 
possibly due to improved diagnostic modalities and greater awareness among surgeons. 
 
It represents a group of neoplasms which developed from different endocrines cells in 
the body. Neuroendocrine tumours arise from enterochromaffin cells located throughout the 
body. Neuroendocrine tumours exhibit a wide spectrum of clinical behaviour ranging from 
indolent to highly aggressive and metastatic. Neuroendocrine tumour is always believed to be 
associated with carcinoid syndrome, but literatures have shown that it is not. Patients with 
carcinoid syndromes may presented with symptoms such as flushing, diarrhoea and epigastric 
pain.  
 
Neuroendocrine tumours can be diagnosed clinically and using various methods such as 
biomarkers, imaging, endoscopy and histopathology. Biomarkers are important as it can give 
clinicians an index of suspicion in diagnosing neuroendocrine tumours. Histopathological 
examination is important to see the grading of the tumour as grading of neuroendocrine 
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tumours is associated with outcome of the patients. Imaging such as CT scan, MRI and PET 
scan can help determining the primary location of tumour and the location of tumour is 
thought to be an important prognostic value in NETs.  
 
In general, neuroendocrine tumours are associated with poor outcome as they usually 
presented late and at late stage of disease. Moreover, there are several prognostic factors 
associated with the outcomes. Literatures have shown that factors such as age, primary 
tumour location, grades by histopathological examination, stages based on imaging, level of 
Chromogranin A and treatment received by patients. 
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1.2 – LITERATURE REVIEW 
  
 
Incidence of NETs is increasing today. In United States alone, there has been a five-fold 
increase in the number of cases over the last 5 years. Modlin reported the incidence to be 2.5-
5 per 100,000 per year (Modlin et al., 2007). The prevalence has recently been calculated by 
Yao to be 35 per 100, 000 per year. In a paper by American Cancer Society in 2014, quoted 
that each year estimated 8,000 people in the United States are diagnosed with a 
neuroendocrine tumour (Yao et al., 2008). Study in England demonstrated the incidence for 
small bowel neuroendocrine tumour is estimated to be from 0.32 per 100,000 per year. 
Meanwhile in Sweden estimated to be from 1.12 per 100,000 per year. Study by Neiderle 
done in Austria showed that the overall incidence was 2.39 per 100 000 per year (Niederle et 
al., 2010).  
 
Neuroendocrine tumours can appear at any ages, the highest being from the fifth decade 
of life onwards. The exception is the carcinoid of the appendix, which occurs with the highest 
incidence at 40 years of age. Study by Yao in 2007 showed that there is a slight overall 
higher incidence of NETs for males (5.35) compared with females (4.76) (Yao et al., 2008). 
In Malaysia, a study done showed that the mean age was 49 years (20–75) (Gunavathy et al., 
2014).  
 
Oberndofer first described these tumours and used the term carcinoid (or “karzinoide”) in 
1907 (Creutzfeldt, 1996). In 1963 Williams and Sandler classified carcinoids according to 
embryogenetic aspects into: foregut (lung, stomach, duodenum, upper jejunum, and 
pancreas), midgut (lower jejunum, ileum, appendix, and cecum), hindgut (colon and rectum). 
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The first WHO classification of endocrine tumours, published in 1980, the term carcinoid 
was applied to most of the neuroendocrine tumours. The carcinoids were divided into: 
enterochromaffin (EC cell), gastrin (G cell), other unspecified carcinoids. In the year 2000, 
WHO came out with a new classification of NETs of the GIT: 1a – well differentiated 
neuroendocrine tumour, 1b - well differentiated neuroendocrine carcinoma, 2 - poorly 
differentiated neuroendocrine carcinoma.  
 
Kloppel and Clemens claimed that the stomach as the most frequent location (22.8% of 
all GEP-NETs) (Klöppel, Perren and Heitz, 2004). This is contrast to studies by Modlin in 
2003 describing NETs of the small intestine most frequently. In Malaysia, pancreatic NETs 
are the most common according to study by Gunavathy in 2014. NETs are characterized by 
their ability to produce peptides that cause characteristic hormonal syndromes. They are more 
indolent, however they can be aggressive and resistant to therapy. Kloppel again in 2004 
demonstrated NETs in the stomach (67.7%), rectum (65%) and appendix (62.7%) were 
usually behaved as benign, those in the small intestine (86.4%), pancreas (75.8%) and colon 
(70.0%) were predominantly malignant (Klöppel, Perren and Heitz, 2004). Yao in 2007 
found that disease stage, primary tumour site, histology, age, sex, race, and period of 
diagnosis were important predictors of outcome. Primary tumour site to be perhaps the most 
useful predictor of outcome in patients with NETs (Yao et al., 2008).  
 
NETs may present with variants of symptoms. Most patients are asymptomatic and the 
tumours are incidentally detected. Symptomatic patients may present with hormonal excess, 
mass effect (e.g. abdominal pain, jaundice, vomiting) due to the primary tumour or 
metastasis. Some tumours don’t overproduce hormones and not causing symptoms. These are 
known as non-functioning NETs. Diagnosis of NETs is difficult. Some patients are treated 
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for different diagnosis first before discovering NETs. This is because the variability of 
presentation and lack of awareness. Clinically “functioning” tumours are detected earlier 
because the secreted hormones produce recognizable symptoms such as flushing and the 
carcinoid syndrome. “Non-functioning” tumours are less likely to be detected unless found 
incidentally or when the primary or metastatic lesion have grown large enough to cause mass 
effects.  
 
NETs can be diagnosed using various methods such as biomarkers, imaging, endoscopy 
and histopathology. Pathological diagnosis is based on histo-morphology, aided by immuno-
histochemistry. The histo-morphology of the tumour shows uniform cells with a wide range 
of arrangement, including polygonal cell nests, ribbons, glands and isolated cell clusters. The 
histological grading is based on mitotic count and Ki-67 activity. Turaga in 2011 stated that 
the grade of tumour relates to its aggressiveness (Turaga and Kvols, 2011). Study by Rindi, 
Hotta, Moyana, and Chaudry claimed that Ki-67 proliferative index (Ki-67 index) has been 
suggested to be useful in predicting the metastatic potential of GI-NETs and survival of 
patients with GI-NETs (Rindi et al., 1999; Moyana et al., 2000; Hotta et al., 2006).  
 
NETs are a challenge to diagnose, stage and treat. A multidisciplinary expertise is 
needed. There should be a multidisciplinary collaborative effort involving 
gastroenterologists, endocrinologists, surgeons, oncologists, pathologists, and interventional 
radiologists. The challenges in managing NETs are variable and unclear natural history of the 
disease, inability to determine the behaviour of the tumour and lack of awareness among 
doctors (Phan et al., 2010). Before treatment can be initiated, the extent of tumour, presence 
of metastases and secretory profile should be determined.  
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The aim of treatment in metastasized disease is to maintain a good quality of life, and at 
the same time control the symptoms and tumour growth. Liang Tao in 2016 claimed that 
prognosis depends on mitotic rates and functional status correlates strongly with survival (Ye 
et al., 2016). According to Yao et al, survival can, however, vary widely across specific types 
of NETs. Median 5-year survival for patients with GI NETs with distant metastases range 
from 5 months for colon tumours to 56 months for small bowel tumours. Yao also claimed 
that metastatic pancreatic NETs are considerably more malignant, with a median 5-year 
survival of only 23 months among patients with distant metastasis (Yao et al., 2008). Modlin 
stated that to improve outcome from NETs, a better understanding of their biology is needed, 
with emphasis on molecular genetics and disease modelling. More-reliable serum markers, 
better tumour localization and identification of small lesions, and histological grading 
systems and classifications with prognostic application are needed (Modlin et al., 2007). 
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1.3 – RATIONALE FOR THE STUDY 
 
 
Neuroendocrine tumour incidence is rising now with the development of new technology 
in detecting the disease. New kind of investigations and imaging helped in detecting the 
disease. The awareness among surgeon also contributed in the rise of the incidence.  
 
The epidemiology of NET in Malaysia are not well documented maybe because it is very 
rare. There are no local studies was done regarding the prognostic factors for neuroendocrine 
tumour. Furthermore, there is no epidemiological data regarding neuroendocrine tumour in 
our institution. The study can tell us the epidemiology of NET in our own institution. 
 
Imaging is needed in finding the primary tumour location. Studies showed that primary 
tumour location is an important factor determining the prognosis of patients with 
neuroendocrine tumour. The study will see the association of primary tumour location with 
the prognosis of patient in term of present of metastasis and disease free survival. We can 
help to stratify patient and help in term of management and prognosis.  
 
Survival rate, disease free progression and life expectancy can be estimated in all NET 
patients. From this, we can ideally plan the management and follow up of NET patients. 
From the study, hopefully we can better treat our neuroendocrine tumour patients. The study 
will also indirectly help our oncologist in deciding their managements. 
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1-TITLE:  
1-a-Primary Tumour Location As A Prognostic Factor For Survival in Neuroendocrine 
Tumour in HUSM: 10 Year Review 
 
 
 
     1-b-This study is a retrospective study to see the association between primary tumour 
location and prognosis of patient with neuroendocrine tumour. This study involves all 
patients who are diagnosed with neuroendocrine tumour in Hospital Universiti Sains 
Malaysia. The patients involving in this study are screened with our inclusions and exclusion 
criteria. List of patients diagnosed with neuroendocrine tumour from January 2005 to 
December 2015 is obtained from record office. The medical records of patients that recruited 
in the study will be reviewed and the data will be entered into the data collection form.  The 
data will be analysed. The study will analysed the association of the primary tumour location 
with the clinical symptoms and signs, biochemical markers, nodal status, metastasis status, 
and survival of patient in neuroendocrine tumour. The literature review of studies done 
before relating to this topic have produced similar results. 
 
2-a-Introduction 
 
Neuroendocrine tumour (NET) is a mass that begins in the parts of the body that produce and 
release hormones. NETs are rare tumours. However, there has been a steady increase in 
incidence and prevalence of NETs over the last decade. This is possibly due to improved 
diagnostic modalities and greater awareness among surgeons. It represents a group of 
neoplasm which are develop from different endocrines cells in the body. NETs arise from 
enterochromaffin cells located throughout the body. NETs exhibit a wide spectrum of clinical 
behaviour ranging from indolent to highly aggressive and metastatic. NETs can be diagnosed 
clinically and using various methods such as biomarkers, imaging, endoscopy and 
histopathology. Histopathological diagnosis is important to see the grading of the tumour. 
Imaging can help determining the primary location of tumour and the location of tumour is 
thought to be an important prognostic value in NETs. 
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2-b-Literature review 
 
Incidence of NETs is increasing today. In United States alone, there has been a five-fold 
increase in the number of cases over the last 5 years. Modlin reported the incidence to be 2.5-
5 per 100,000 per year (Modlin, 2007). The prevalence has recently been calculated by Yao 
to be 35 per 100, 000 per year (Yao et al., 2008). In a paper by American Cancer Society in 
2014, quoted that each year estimated 8,000 people in the United States are diagnosed with a 
neuroendocrine tumour. Study in England demonstrated the incidence for small bowel 
neuroendocrine tumour is estimated to be from 0.32 per 100,000 per year. Meanwhile in 
Sweden estimated to be from 1.12 per 100,000 per year (Hemminki and Li, 2001). Study by 
Neiderle done in Austria showed that the overall incidence was 2.39 per 100 000 per year 
(Niederle et al., 2010). Neuroendocrine tumours can appear at any ages, the highest being 
from the fifth decade of life onwards. The exception is the carcinoid of the appendix, which 
occurs with the highest incidence at 40 years of age. Study by Yao in 2007 showed that there 
is a slight overall higher incidence of NETs for males (5.35) compared with females (4.76). 
In Malaysia, a study done showed that the mean age was 49 years (20–75) (Gunavathy et al., 
2014). Oberndofer first described these tumours and used the term carcinoid (or 
“karzinoide”) in 1907 (Oberndorfer, 1907). In 1963 Williams and Sandler classified 
carcinoids according to embryogenetic aspects into: foregut (lung, stomach, duodenum, upper 
jejunum, and pancreas), midgut (lower jejunum, ileum, appendix, and cecum), hindgut (colon 
and rectum) (Williams and Sandler, 2017). The first WHO classification of endocrine 
tumours, published in 1980, the term carcinoid was applied to most of the neuroendocrine 
tumours. The carcinoids were divided into: enterochromaffin (EC cell), gastrin (G cell), other 
unspecified carcinoids. In the year 2000, WHO came out with a new classification of NETs 
of the GIT: 1a – well differentiated neuroendocrine tumour, 1b - well differentiated 
neuroendocrine carcinoma, 2 - poorly differentiated neuroendocrine carcinoma. Kloppel 
claimed that the stomach as the most frequent location (22.8% of all GEP-NETs) (Klöppel, 
Perren and Heitz, 2004). This is contrast to studies by Modlin in 2003 describing NETs of the 
small intestine most frequently. In Malaysia, pancreatic NETs are the most common 
according to study by Gunavathy in 2014. NETs are characterized by their ability to produce 
peptides that cause characteristic hormonal syndromes. They are more indolent, however they 
can be aggressive and resistant to therapy. Kloppel again in 2004 demonstrated NETs in the 
stomach (67.7%), rectum (65%) and appendix (62.7%) were usually behaved as benign, those 
in the small intestine (86.4%), pancreas (75.8%) and colon (70.0%) were predominantly 
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malignant. Yao in 2008 found that disease stage, primary tumour site, histology, age, sex, 
race, and period of diagnosis were important predictors of outcome. Primary tumour site to 
be perhaps the most useful predictor of outcome in patients with NETs (Yao et al., 2008). 
NETs may present with variants of symptoms. Most patients are asymptomatic and the 
tumours are incidentally detected (de Miguel Novoa et al., 2014). Symptomatic patients may 
present with hormonal excess, mass effect (e.g. abdominal pain, jaundice, vomiting) due to 
the primary tumour or metastasis. Some tumours don’t overproduce hormones and not 
causing symptoms. These are known as non-functioning NETs. Diagnosis of NETs is 
difficult. Some patients are treated for different diagnosis first before discovering NETs. This 
is because the variability of presentation and lack of awareness. Clinically “functioning” 
tumours are detected earlier because the secreted hormones produce recognizable symptoms 
such as flushing and the carcinoid syndrome. “Non-functioning” tumours are less likely to be 
detected unless found incidentally or when the primary or metastatic lesion have grown large 
enough to cause mass effects. NETs can be diagnosed using various methods such as 
biomarkers, imaging, endoscopy and histopathology. Pathological diagnosis is based on 
histo-morphology, aided by immune-histochemistry. The histo-morphology of the tumour 
shows uniform cells with a wide range of arrangement, including polygonal cell nests, 
ribbons, glands and isolated cell clusters. The histological grading is based on mitotic count 
and Ki-67 activity. Turaga in 2011 stated that the grade of tumour relates to its 
aggressiveness (Turaga, 2011).  
 
Grade Mitotic count per 10hpf Ki-67 index 
G1 <2 <2% 
G2 2-20 3-20% 
G3 >20 >20% 
 
 
Study by Rindi, Hotta and Moyana claimed that Ki-67 proliferative index (Ki-67 index) has 
been suggested to be useful in predicting the metastatic potential of GI-NETs and survival of 
patients with GI-NETs (Rindi,1999; Hotta, 2006; Moyana, 2000). NETs are a challenge to 
diagnose, stage and treat. A multidisciplinary expertise is needed. There should be a 
multidisciplinary collaborative effort involving gastroenterologists, endocrinologists, 
surgeons, oncologists, pathologists, and interventional radiologists. The challenges in 
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managing NETs are variable and unclear natural history of the disease, inability to determine 
the behaviour of the tumour and lack of awareness among doctors. Before treatment can be 
initiated, the extent of tumour, presence of metastases and secretory profile should be 
determined. The aim of treatment in metastasized disease is to maintain a good quality of life, 
and at the same time control the symptoms and tumour growth. Ye in 2016 claimed that 
prognosis depends on mitotic rates and functional status correlates strongly with survival (Ye 
et al., 2016). According to Yao et al, survival can, however, vary widely across specific types 
of NETs. Median 5-year survival for patients with GI NETs with distant metastases range 
from 5 months for colon tumours to 56 months for small bowel tumours. Yao also claimed 
that metastatic pancreatic NETs are considerably more malignant, with a median 5-year 
survival of only 23 months among patients with distant metastasis (Yao et al., 2008). Modlin 
stated that to improve outcome from NETs, a better understanding of their biology is needed, 
with emphasis on molecular genetics and disease modelling. More-reliable serum markers, 
better tumour localization and identification of small lesions, and histological grading 
systems and classifications with prognostic application are needed. 
 
 
2-c-Problem statement & rationale of studies. 
 
Incidence NETs is increasing today even it is still a rare disease. However, the disease is 
difficult to detect. Surgeons and physicians having the difficulties to diagnose and even to 
treat the disease. These are due to the variable way of presentation of NETs. Most of the 
patient presented late and presented with a metastasized disease. The epidemiology of NET 
in Malaysia are not well documented maybe because it is very rare. So far in Kelantan, there 
is no paper or article about the epidemiology of NET in this region. By performing this study, 
we can obtain the epidemiology for our own institution. Neuroendocrine tumour can occur in 
anywhere in the body. Imaging are required to locate the primary tumour location in most of 
the cases. Several studies have showed that primary tumour location is an important factor 
determining the prognosis of patients with neuroendocrine tumour. The study will see the 
association of primary tumour location with the prognosis of patient in term of present of 
metastasis and disease free survival. From this study, we can help to stratify patient and help 
in term of management and prognosis. Survival rate, disease free progression and life 
expectancy can be estimated in all NET patients. From this, we can ideally plan the 
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management and follow up of NET patients. Hopefully, this study will also help the oncology 
team in deciding their managements. 
2-d-Objectives 
  
 
General objective 
 
 To study the correlation of the primary tumor location with the prognosis 
in neuroendocrine tumors in Hospital University Sains Malaysia (HUSM). 
 
 
Specific objectives 
 
 First specific objective: To determine the epidemiology of neuroendocrine 
tumor in HUSM. 
 Second specific objective: To determine the association of primary tumor 
location with the present of metastasis. 
 Third specific objective: To determine the relation of primary tumor 
location with 5years disease free survival in NETs. 
 
 
3-Research Methodology 
 
3-a Trial Design 
 
• This is a retrospective record review involving patient diagnosed with neuroendocrine 
tumour in HUSM. 
     
 
4-a Study population 
 
     4-a-i Reference population 
• All patients in Hospital Universiti Sains Malaysia 
 
    4-a-ii Source population 
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• All patients diagnosed to have Neuroendocrine Tumor in Hospital Universiti 
Sains Malaysia. 
 
    4-a-iii Inclusion criteria 
 All patients who have been diagnosed neuroendocrine tumor with established 
primary tumor location in Hospital University Sains Malaysia. 
 
    4-a-iv Exclusion criteria 
 All patients who have been diagnosed neuroendocrine tumor but without known 
histopathological examination result 
 Incomplete documentation of patient’s case note 
 Patient with NET with concomitant other malignancy 
 
 
 
4-b Study settings 
 
 
4-b-i Study Location 
• Hospital Universiti Sains Malaysia 
 
 
4-b-ii Study Duration 
• The study includes all patients who diagnosed with NET from January 2005 to 
December 2015. The data collection will be started after ethical approval. 
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5-Sampling size. 
 
5-a-i Sample size determination 
The sample size was determined by Two Mean formula by using PS Power and Sample Size 
Calculation software Version 3.0.10 according to study by Schoenfeld & Richter (1982) 
 
 
 
Type 1 error (a) 0.05 
Power  0.8 
Median survival time on control in months (m1) 15 
Median survival time on experimental in months (m2) 6 
Accrual time in which patient are recruited in months (A) 120 
Additional follow up time after end of recruitment in months (F) 60 
Ratio of control to experiment patient (m) 1 
 
 
 
Sample size experiment: 19 
 
Sample size control: 19 
 
Total sample size: 38 
 
 
 
 
 
 
 
 
 
 
 17 
 
 
 
 
 
6-Research Tool 
 
After ethical approval, a list of patients who diagnosed with Neuroendocrine Tumor in 
between January 2005 to December 2015 will be obtained from the record in the record 
office. Patients who fulfilled the inclusion and exclusion criteria will be recruited in the 
study. The data of patients will be obtained by retrospective review of patient’s medical 
records. The data will be entered in a data collection form.   
 
 
7-Data collection  
Data collection will be recorded in a data collection form. The following information was 
recorded: patient’s demographic, patient’s presentations, primary tumour location, operative 
information, histopathological examinations (HPE) reports, patient’s grading and staging, and 
patient’s current status. 
 
8-Proposed data analysis  
Data entry and analysis will be done by using SPSS version 22. Descriptive analysis will be 
done using mean and standard deviation for numerical variables and frequency and 
proportion for categorical variables.  
Each specific objective will be analysed using different methods: Sample Size Calculation 
v1.7.1 by Dr Wan Nor Arifin, available at medic.usm.my.  
. Kaplan-Meier plot  
. Log rank test 
. Cox proportional hazard regression 
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9-Ethical Issues  
1. Declaration of Conflict of Interest.  
There is no conflict of interest in this study. 
2. Handling Privacy and Confidentiality Issues 
Throughout this study, all personal information and data will not be disclosed unless 
required by law. Subject’s confidentiality will be protected; no name or identifiable 
information will be collected. Data will be protected through password setting to 
access the database and securely locked. The data is only accessible by researchers 
involve in this study. The data will be used and remain directly available up to 
completion of the study. Thereafter, the data will be compressed with encryption and 
archived in a flash drive after proper documentation. This is to be destroyed by 
formatting the flash drive after a 5- years maintenance period determined by the date 
of its formal closure. We define the formal 15 closure as the submission of a closure 
report to the National Medical Research Registry of Malaysia. Subject’s data and 
information will be kept confidential and will be known by research team only. Only 
aggregated (grouped) results will be presented and submitted to local or international 
peer-reviewed medical journals and relevant government ministries. 
3. Publication and Presentation 
The data and results from this study will be presented either in poster format or 
published in any upcoming conference without revealing any subjects’ private 
information. 
4. Community Benefits 
Hopefully the information and the result from this study can be beneficial for the 
researcher to evaluate regarding management of neuroendocrine tumor and  will 
enable us to formulate steps that can enhance the quality of service given by health 
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facilities in the future.  
 
10-Flow chart 
 
 
List of patients diagnosed with NETs from January 2005 to December 2015 is obtained from 
record office. 
 ↓  
Recruitment of patients who fulfilling the inclusion and exclusion criteria 
 ↓  
Review of medical records of patients that recruited in the study 
 ↓  
Data from medical records entered in the data collection form 
 ↓  
Data collection and statistical analysis 
 ↓  
Report and manuscript write up 
      ↓ 
      Submission 
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11-Gantt chart 
 
 
 
 Task S O N D J F M A M J J A S 0 N D 
1 Department presentation ✔                
2 Research Proposal ✔ ✔               
3 Ethical Meeting   ✔ ✔ ✔            
4 Discussion with supervisor ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
5 Data Collection      ✔ ✔ ✔ ✔        
6 Data Analysis        ✔ ✔ ✔ ✔      
7 Report Preparation         ✔ ✔ ✔ ✔ ✔    
8 Submission of draft             ✔ ✔   
9 Research Revision               ✔ ✔  
10 Submission of final research              ✔ ✔ ✔ 
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Data Collection Form    Sample No:  
 
Demographic : 
 
Age :    Sex: M/ F    Ethnic:    
Patients first presentation : 
Patient’s symptoms : Carcinoid/Mass effect/Incidental 
Duration of symptoms : _________________ 
 
Surgery : Yes / No 
Date of surgery: ____________  
Surgeon : ____________________ 
Indication for surgery: _____________ 
Surgical procedure :___________________ 
 
 
Biopsy/HPE: Yes / No 
Tumour Size :   
Type  : _______________ 
Tumour location : ________________________ 
Histopathological diagnosis: _______________________________ 
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Imaging : Yes / No 
Type of Imaging : _____________________ 
Site of Tumour: ________________________ 
Lymph node involvement : Yes / No 
Metastasis: Regional/Distant 
Stage : 1 / 2/ 3/ 4 
 
Biomarkers : Yes /No 
Serum CgA : _____________ 
Others : __________________ 
 
 
Final Diagnosis :         
 
 
Patient status : Alive/ Death 
Date of death : _________________ 
Disease recurrence: Yes/ No 
Complications : Yes / No 
Chemotherapy : Yes / No 
Radiotherapy : Yes / No 
Follow up : Yes/No 
Follow up duration : __________________ 
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